JP2001501920A - ヒトvegf受容体タンパク質(kdr)の細胞外ドメインに対するモノクローナル抗体 - Google Patents
ヒトvegf受容体タンパク質(kdr)の細胞外ドメインに対するモノクローナル抗体Info
- Publication number
- JP2001501920A JP2001501920A JP10513245A JP51324598A JP2001501920A JP 2001501920 A JP2001501920 A JP 2001501920A JP 10513245 A JP10513245 A JP 10513245A JP 51324598 A JP51324598 A JP 51324598A JP 2001501920 A JP2001501920 A JP 2001501920A
- Authority
- JP
- Japan
- Prior art keywords
- kdr
- antibodies
- antibody
- human vegf
- vegf receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
- A61K51/103—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against receptors for growth factors or receptors for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.ヒトVEGF受容体KDRの細胞外ドメイン1〜7の範囲内に位置するエピ トープに対して特異的に結合するモノクローナル抗体。 2.抗体がヒトVEGF受容体KDRの細胞外ドメイン6および7に位置するエ ピトープに対して特異的に結合することを特徴とする、請求項1記載のモノクロ ーナル抗体。 3.抗体が、抗体AM2−7−9、AM2−10−1、AM5−1−2、AM5 −10−13およびAM2−4−1であることを特徴とする、請求項2記載のモ ノクローナル抗体。 4.抗体が、抗体AM2−7−9およびAM2−10−1であることを特徴とす る、請求項2または3記載のモノクローナル抗体。 5.ウエスタンブロット、免疫沈降、ELTSA、FACS分析において、かつ 間接免疫蛍光検鏡法においての請求項1から4までのいずれか1項記載のモノク ローナル抗体の使用。 6.免疫組織化学における請求項1から4までのいずれか1項記載のモノクロー ナル抗体の使用。 7.小さいアゴニスト分子およびアンタゴニスト分子に関するスクリーニングお よび突然変異受容体サブタイプの検出における請求項1から4までのいずれ か1項記載のモノクローナル抗体の使用。 8.診断における請求項1から4までのいずれか1項記載のモノクローナル抗体 の使用。 9.モノクローナル抗体を、適当なコントラスト増強物質と組み合わせて結合さ せ、その形で使用することを特徴とする請求項8記載の使用。 10.抗体に結合したコントラスト増強物質が99mテクネチウムであることを特 徴とする、請求項8または9記載の使用。 11.適当な毒性物質と結合させた請求項1から4までのいずれか1項記載のモ ノクローナル抗体の使用。 12.血管形成依存性表現型、例えば腫瘍、リウマチ様関節炎または乾癖におけ る請求項11記載の使用。 13.転移の場合における請求項11または12記載の使用。 14.組み換え“単一鎖抗体”の製造における、本発明による抗体のH鎖および L鎖をコードするmRNAの使用。 15.ウエスタンブロット、免疫沈降、ELISA、FACS分析、間接免疫蛍 光検鏡法および免疫組織化学における請求項14記載のmRNAによってコード される組み換え抗体の使用。 16.以下の工程: 1.モノクローナル抗体AM2−7−9、AM2−10−1、AM5−1−2 、AM5−10−13またはAM2−4−1を、捕獲抗体として、結合緩衝液中 の濃度1〜10μg/mlでELISAプレート上に精製した形で結合させ、次 いで過剰な結合部位をブロッキング緩衝液で閉塞し、 2.細胞または組織分析物を適当な溶解緩衝液中で製造し、 3.プレートを洗浄緩衝液中で洗浄してから、溶解物を適用し、 4.試料中の測定すべきKDRタンパク質を、検量線として組み換えKDRタ ンパク質を使用して定量し、 5.次いで、分析すべき組織および細胞溶解物を試験系に導入し、 6.室温で2時間インキュベートし、 7.次いで、ELISAプレートを洗浄し、 8.“捕獲した”KDRの測定を、ポリクローナル抗KDR抗血清によって実 施し、かつ最終的に 9.発色性、化学発光性または放射性物質による検出を実施する を特徴とする、細胞溶解物または組織分析物におけるヒトVEGF受容体KDR の測定方法。 17.チロシンホスホリル化KDRを測定するキナーゼテスト法の形で実施する 方法であることを特徴と する、請求項16記載の方法。 18.組み換えホスホリル化KDRを基準タンパク質として使用することを特徴 とする、請求項16または17記載の方法。 19.前記の方法の工程8で使用されるポリクローナル抗KDR抗血清がポリク ローナル抗ホスホチロシン抗血清またはモノクローナル抗ホスホチロシン抗体で あることを特徴とする、請求項16から18までのいずれか1項記載の方法。 20.前記の方法の工程9における検出で使用される物質が、適当な発色性また は化学発光基質を有するペルオキシダーゼ標識二次抗体であることを特徴とする 、請求項16から19までのいずれか1項記載の方法。 21.前記の方法の工程2で使用される溶解緩衝液が二価イオン1〜5mMおよ びグリセロール1〜15%を含有することを特徴とする、請求項16から20ま でのいずれか1項記載の方法。 22.前記の方法の工程2で使用される溶解緩衝液が1〜2mMの二価イオンお よび5〜12%のグリセロールを含有することを特徴とする、請求項16から2 0までのいずれか1項記載の方法。 23.前記の方法の工程2で使用される溶解緩衝液が1.5mMの二価イオンお よび10%のグリセロールを含有することを特徴とする、請求項16から2 0までのいずれか1項記載の方法。 24.二価イオンがマグネシウムであることを特徴とする、請求項21から23 までのいずれか1項記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19638745A DE19638745C2 (de) | 1996-09-11 | 1996-09-11 | Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR) |
DE19638745.0 | 1996-09-11 | ||
PCT/EP1997/004928 WO1998011223A1 (en) | 1996-09-11 | 1997-09-09 | Monoclonal antibodies against the extracellular domain of human vegf-receptor protein (kdr) |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2001501920A true JP2001501920A (ja) | 2001-02-13 |
Family
ID=7806450
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP10513245A Ceased JP2001501920A (ja) | 1996-09-11 | 1997-09-09 | ヒトvegf受容体タンパク質(kdr)の細胞外ドメインに対するモノクローナル抗体 |
Country Status (12)
Country | Link |
---|---|
US (1) | US6344339B1 (ja) |
EP (1) | EP0925359A1 (ja) |
JP (1) | JP2001501920A (ja) |
AU (1) | AU730287B2 (ja) |
CA (1) | CA2265927A1 (ja) |
DE (1) | DE19638745C2 (ja) |
HU (1) | HUP9904052A3 (ja) |
IL (1) | IL128406A0 (ja) |
NO (1) | NO991162L (ja) |
PL (1) | PL332034A1 (ja) |
WO (1) | WO1998011223A1 (ja) |
ZA (1) | ZA978204B (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007518088A (ja) * | 2004-01-06 | 2007-07-05 | バドリラ・リミテッド | 結合を定量化する薬剤および方法 |
Families Citing this family (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2299099A (en) * | 1998-02-04 | 1999-08-23 | Kyowa Hakko Kogyo Co. Ltd. | Antibodies against human vegf receptor kdr |
DE19813774A1 (de) * | 1998-03-27 | 1999-09-30 | Max Planck Gesellschaft | Parapockenvirus-kodierter vaskulärer Endothelzell Wachstumsfaktor (PPV-VEGF) |
NO983911D0 (no) * | 1998-08-26 | 1998-08-26 | Norsk Hydro As | Alginatkapsler til bruk ved behandling av hjernesvulst |
EP1126842A2 (en) * | 1998-11-06 | 2001-08-29 | Basf Aktiengesellschaft | Inhibition of the formation of vascular hyperpermeability |
WO2000044777A1 (en) * | 1999-01-29 | 2000-08-03 | Imclone Systems Incorporated | Antibodies specific to kdr and uses thereof |
EP1130032A1 (en) * | 2000-02-28 | 2001-09-05 | Gesellschaft für biotechnologische Forschung mbH (GBF) | Single-chain antibodies recognizing the human vascular endothelial growth factor receptor-2 (VEGFR-2/KDR) |
EP2762140B1 (en) | 2001-02-19 | 2017-03-22 | Novartis AG | Treatment of solid brain tumours with a rapamycin derivative |
CZ299756B6 (cs) | 2001-05-16 | 2008-11-12 | Novartis Ag | Kombinace s obsahem N-{5-[4-(4-methyl-piperazino-methyl)benzoylamido]-2-methylfenyl}-4-(3-pyridyl)-2-pyrimidin-aminu k lécení proliferativních onemocnení |
TWI315982B (en) | 2001-07-19 | 2009-10-21 | Novartis Ag | Combinations comprising epothilones and pharmaceutical uses thereof |
GB0124317D0 (en) | 2001-10-10 | 2001-11-28 | Celltech R&D Ltd | Biological products |
GB0206215D0 (en) | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
DK1505959T3 (da) | 2002-05-16 | 2009-02-23 | Novartis Ag | Anvendelse af EDG-receptorbindingsmidler ved cancer |
EP2270042B1 (en) * | 2002-09-12 | 2015-01-14 | Oncotherapy Science, Inc. | KDR peptides and vaccines comprising the same |
US7250289B2 (en) * | 2002-11-20 | 2007-07-31 | Affymetrix, Inc. | Methods of genetic analysis of mouse |
MY150088A (en) | 2003-05-19 | 2013-11-29 | Irm Llc | Immunosuppressant compounds and compositions |
CA2524048C (en) | 2003-05-19 | 2013-06-25 | Irm Llc | Immunosuppressant compounds and compositions |
GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
CA2590671A1 (en) | 2004-11-18 | 2006-05-26 | Imclone Systems Incorporated | Antibodies against vascular endothelial growth factor receptor-1 |
US20060222595A1 (en) * | 2005-03-31 | 2006-10-05 | Priyabrata Mukherjee | Nanoparticles for therapeutic and diagnostic applications |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
WO2007038459A2 (en) | 2005-09-27 | 2007-04-05 | Novartis Ag | Carboxyamine compounds and their use in the treatment of hdac dependent diseases |
US9006224B2 (en) | 2005-11-21 | 2015-04-14 | Novartis Ag | Neuroendocrine tumor treatment |
CN1987468B (zh) * | 2005-12-23 | 2012-01-11 | 上海交通大学医学院附属仁济医院 | 血管内皮生长因子时间分辨荧光免疫分析方法及试剂盒 |
EP2004163B1 (en) | 2006-04-05 | 2014-09-17 | Novartis Pharma AG | Combination of everolimus and vinorelbine |
NZ572299A (en) | 2006-05-09 | 2010-07-30 | Novartis Ag | Combination comprising a substituted 3,5-diphenyl-1,2,4-triazole and a platinum compound and use thereof |
GB0612721D0 (en) | 2006-06-27 | 2006-08-09 | Novartis Ag | Organic compounds |
WO2008037477A1 (en) | 2006-09-29 | 2008-04-03 | Novartis Ag | Pyrazolopyrimidines as p13k lipid kinase inhibitors |
WO2008066655A2 (en) | 2006-11-02 | 2008-06-05 | Yale University | Assessment of oocyte competence |
US9073997B2 (en) * | 2007-02-02 | 2015-07-07 | Vegenics Pty Limited | Growth factor antagonists for organ transplant alloimmunity and arteriosclerosis |
EP2120900A2 (en) | 2007-02-15 | 2009-11-25 | Novartis AG | Combination of lbh589 with other therapeutic agents for treating cancer |
TWI436775B (zh) | 2007-08-24 | 2014-05-11 | Oncotherapy Science Inc | 以抗原胜肽合併化療藥劑治療胰臟癌 |
EA019033B1 (ru) | 2008-03-26 | 2013-12-30 | Новартис Аг | Ингибиторы дезацетилазы в, основанные на гидроксамате |
CN102076844B (zh) | 2008-06-30 | 2013-08-07 | 成血管细胞系统公司 | 采用组合疗法的眼病和过度血管新生的治疗 |
US20110223241A1 (en) | 2008-10-16 | 2011-09-15 | Celator Pharmaceuticals, Inc. | Combination methods and compositions |
JP5805538B2 (ja) * | 2008-11-07 | 2015-11-04 | リサーチ ディベロップメント ファウンデーション | Cripto/GSP78複合体形成およびシグナル伝達を阻害するための組成物および方法 |
JP2012512885A (ja) | 2008-12-18 | 2012-06-07 | ノバルティス アーゲー | 新規な塩 |
EP2379498B1 (en) | 2008-12-18 | 2015-01-21 | Novartis AG | Polymorphic form of 1-(4-{1-[(e)-4-cyclohexyl-3-trifluoromethyl-benzyloxyimino]-ethyl}-2-ethyl-benzyl) -azetidine-3-carboxylic acid |
AU2009335924B2 (en) | 2008-12-18 | 2012-11-08 | Novartis Ag | Hemifumarate salt of 1- [4- [1- ( 4 -cyclohexyl-3 -trifluoromethyl-benzyloxyimino ) -ethyl] -2 -ethyl-benzyl] -a zetidine-3-carboxylic acid |
WO2010088335A1 (en) | 2009-01-29 | 2010-08-05 | Novartis Ag | Substituted benzimidazoles for the treatment of astrocytomas |
TW201109029A (en) | 2009-06-11 | 2011-03-16 | Oncotherapy Science Inc | Vaccine therapy for choroidal neovascularization |
ES2475945T3 (es) | 2009-06-26 | 2014-07-11 | Novartis Ag | Derivados imidazolidin-2 -ona 1,3-disustituida como inhibidores de CYP 17 |
US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
BR112012003262A8 (pt) | 2009-08-12 | 2016-05-17 | Novartis Ag | compostos de hidrazona heterocíclica e seus usos para tratar câncer e inflamação |
IN2012DN01961A (ja) | 2009-08-17 | 2015-08-21 | Intellikine Llc | |
CA2771432A1 (en) | 2009-08-20 | 2011-02-24 | Novartis Ag | Heterocyclic oxime compounds |
JP2013503129A (ja) | 2009-08-26 | 2013-01-31 | ノバルティス アーゲー | テトラ−置換ヘテロアリール化合物ならびにmdm2および/またはmdm4モジュレーターとしてのそれらの使用 |
CA2773661A1 (en) | 2009-09-10 | 2011-03-17 | Novartis Ag | Ether derivatives of bicyclic heteroaryls |
CN102596951B (zh) | 2009-11-04 | 2015-04-15 | 诺华股份有限公司 | 用作mek抑制剂的杂环磺酰胺衍生物 |
EP2504339A1 (en) | 2009-11-25 | 2012-10-03 | Novartis AG | Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls |
US8614239B2 (en) | 2009-12-08 | 2013-12-24 | Novartis Ag | Heterocyclic sulfonamide derivatives |
CU24130B1 (es) | 2009-12-22 | 2015-09-29 | Novartis Ag | Isoquinolinonas y quinazolinonas sustituidas |
US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
JP2013532149A (ja) | 2010-06-17 | 2013-08-15 | ノバルティス アーゲー | ピペリジニル置換1,3−ジヒドロ−ベンゾイミダゾール−2−イリデンアミン誘導体 |
JP2013528635A (ja) | 2010-06-17 | 2013-07-11 | ノバルティス アーゲー | ビフェニル置換1,3−ジヒドロ−ベンゾイミダゾール−2−イリデンアミン誘導体 |
WO2012035078A1 (en) | 2010-09-16 | 2012-03-22 | Novartis Ag | 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS |
WO2012107500A1 (en) | 2011-02-10 | 2012-08-16 | Novartis Ag | [1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase |
EP2678016B1 (en) | 2011-02-23 | 2016-08-10 | Intellikine, LLC | Heterocyclic compounds and uses thereof |
CN103492390A (zh) | 2011-03-08 | 2014-01-01 | 诺瓦提斯公司 | 氟苯基双环杂芳基化合物 |
CA2834224A1 (en) | 2011-04-28 | 2012-11-01 | Novartis Ag | 17.alpha.-hydroxylase/c17,20-lyase inhibitors |
JP2014517004A (ja) | 2011-06-09 | 2014-07-17 | ノバルティス アーゲー | 複素環スルホンアミド誘導体 |
EP2721008B1 (en) | 2011-06-20 | 2015-04-29 | Novartis AG | Hydroxy substituted isoquinolinone derivatives as p53 (mdm2 or mdm4) inhibitors |
WO2012175487A1 (en) | 2011-06-20 | 2012-12-27 | Novartis Ag | Cyclohexyl isoquinolinone compounds |
AU2012300279A1 (en) | 2011-08-26 | 2014-04-03 | Merrimack Pharmaceuticals, Inc. | Tandem Fc bispecific antibodies |
MX339302B (es) | 2011-09-15 | 2016-05-19 | Novartis Ag | 3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como cinasas de tirosina. |
CN104080787B (zh) | 2011-11-29 | 2016-09-14 | 诺华股份有限公司 | 吡唑并吡咯烷化合物 |
WO2013096049A1 (en) | 2011-12-23 | 2013-06-27 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
KR20140104047A (ko) | 2011-12-23 | 2014-08-27 | 노파르티스 아게 | Bcl2와 결합 파트너의 상호작용을 억제하기 위한 화합물 |
US20140357666A1 (en) | 2011-12-23 | 2014-12-04 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
US20140350014A1 (en) | 2011-12-23 | 2014-11-27 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
US20140357633A1 (en) | 2011-12-23 | 2014-12-04 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
UY34591A (es) | 2012-01-26 | 2013-09-02 | Novartis Ag | Compuestos de imidazopirrolidinona |
ES2894830T3 (es) | 2012-04-03 | 2022-02-16 | Novartis Ag | Productos combinados con inhibidores de tirosina·cinasa y su uso |
CN104321325B (zh) | 2012-05-24 | 2016-11-16 | 诺华股份有限公司 | 吡咯并吡咯烷酮化合物 |
EP2948451B1 (en) | 2013-01-22 | 2017-07-12 | Novartis AG | Substituted purinone compounds |
WO2014115080A1 (en) | 2013-01-22 | 2014-07-31 | Novartis Ag | Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction |
JP2016510755A (ja) | 2013-03-06 | 2016-04-11 | メリマック ファーマシューティカルズ インコーポレーティッド | 抗C−METタンデムFc二重特異性抗体 |
WO2014151147A1 (en) | 2013-03-15 | 2014-09-25 | Intellikine, Llc | Combination of kinase inhibitors and uses thereof |
WO2014155268A2 (en) | 2013-03-25 | 2014-10-02 | Novartis Ag | Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity |
EP2994758B1 (en) | 2013-05-08 | 2017-12-20 | Opthea Limited | Biomarkers for age-related macular degeneration (amd) |
US9227969B2 (en) | 2013-08-14 | 2016-01-05 | Novartis Ag | Compounds and compositions as inhibitors of MEK |
WO2015022663A1 (en) | 2013-08-14 | 2015-02-19 | Novartis Ag | Compounds and compositions as inhibitors of mek |
WO2015022664A1 (en) | 2013-08-14 | 2015-02-19 | Novartis Ag | Compounds and compositions as inhibitors of mek |
TW201605450A (zh) | 2013-12-03 | 2016-02-16 | 諾華公司 | Mdm2抑制劑與BRAF抑制劑之組合及其用途 |
US11033621B2 (en) * | 2014-06-09 | 2021-06-15 | Biomed Valley Discoveries, Inc. | Combination therapies targeting tumor-associated stroma or tumor cells |
US10195208B2 (en) | 2014-07-31 | 2019-02-05 | Novartis Ag | Combination therapy |
MX2017004007A (es) | 2014-09-28 | 2018-05-07 | Univ California | Modulacion de celulas mieloides estimulantes y no estimulantes. |
CN109072241A (zh) | 2016-02-08 | 2018-12-21 | 维特里萨医疗公司 | 具有改善的玻璃体内半衰期的组合物及其用途 |
US10543231B2 (en) | 2017-05-19 | 2020-01-28 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
KR20200015921A (ko) * | 2017-07-03 | 2020-02-13 | 재단법인 생물기술개발중심 | 항-vegfr 항체 및 이의 사용 |
US12023353B2 (en) | 2017-10-18 | 2024-07-02 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Methods and compounds for improved immune cell therapy |
CR20200303A (es) | 2017-12-12 | 2020-12-23 | Pionyr Immunotherapeutics Inc | Anticuerpos anti-trem2 y métodos relacionados |
EP3730483B1 (en) | 2017-12-21 | 2023-08-30 | Hefei Institutes of Physical Science, Chinese Academy of Sciences | Class of pyrimidine derivative kinase inhibitors |
WO2021097256A1 (en) | 2019-11-14 | 2021-05-20 | Cohbar, Inc. | Cxcr4 antagonist peptides |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1173991C (zh) | 1992-11-13 | 2004-11-03 | 马克斯普朗克科学促进协会 | 作为血管内皮生长因子受体的f1k-1 |
US5861499A (en) * | 1994-02-10 | 1999-01-19 | Imclone Systems Incorporated | Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain |
US5840301A (en) | 1994-02-10 | 1998-11-24 | Imclone Systems Incorporated | Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors |
-
1996
- 1996-09-11 DE DE19638745A patent/DE19638745C2/de not_active Expired - Fee Related
-
1997
- 1997-09-09 US US09/254,640 patent/US6344339B1/en not_active Expired - Fee Related
- 1997-09-09 CA CA002265927A patent/CA2265927A1/en not_active Abandoned
- 1997-09-09 JP JP10513245A patent/JP2001501920A/ja not_active Ceased
- 1997-09-09 HU HU9904052A patent/HUP9904052A3/hu unknown
- 1997-09-09 AU AU46222/97A patent/AU730287B2/en not_active Ceased
- 1997-09-09 EP EP97944862A patent/EP0925359A1/en not_active Withdrawn
- 1997-09-09 WO PCT/EP1997/004928 patent/WO1998011223A1/en not_active Application Discontinuation
- 1997-09-09 IL IL12840697A patent/IL128406A0/xx unknown
- 1997-09-09 PL PL97332034A patent/PL332034A1/xx unknown
- 1997-09-11 ZA ZA9708204A patent/ZA978204B/xx unknown
-
1999
- 1999-03-10 NO NO991162A patent/NO991162L/no not_active Application Discontinuation
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007518088A (ja) * | 2004-01-06 | 2007-07-05 | バドリラ・リミテッド | 結合を定量化する薬剤および方法 |
JP4829797B2 (ja) * | 2004-01-06 | 2011-12-07 | バドリラ・リミテッド | 結合を定量化する薬剤および方法 |
Also Published As
Publication number | Publication date |
---|---|
DE19638745C2 (de) | 2001-05-10 |
IL128406A0 (en) | 2000-01-31 |
HUP9904052A2 (hu) | 2000-03-28 |
US6344339B1 (en) | 2002-02-05 |
EP0925359A1 (en) | 1999-06-30 |
PL332034A1 (en) | 1999-08-16 |
DE19638745A1 (de) | 1998-03-12 |
AU730287B2 (en) | 2001-03-01 |
HUP9904052A3 (en) | 2002-01-28 |
NO991162D0 (no) | 1999-03-10 |
NO991162L (no) | 1999-05-06 |
CA2265927A1 (en) | 1998-03-19 |
WO1998011223A1 (en) | 1998-03-19 |
ZA978204B (en) | 1998-03-03 |
AU4622297A (en) | 1998-04-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2001501920A (ja) | ヒトvegf受容体タンパク質(kdr)の細胞外ドメインに対するモノクローナル抗体 | |
US10775383B2 (en) | PD-L1 antibodies and uses thereof | |
US8440807B2 (en) | A34 and A33-like 3 DNA protein, antibodies thereto and methods of treatment using same | |
US5863739A (en) | Assay and kit for the detection of α platelet derived growth factor receptor | |
RU2725825C2 (ru) | Антитела и методы анализа для обнаружения рецептора фолиевой кислоты 1 | |
US20030219827A1 (en) | Phospho-specific antibodies to Flt3 and uses thereof | |
JP2017524725A (ja) | 抗b7−h3抗体及びその診断用途 | |
JP6129956B2 (ja) | 抗c−Met抗体 | |
JP5078015B2 (ja) | 尿路上皮ガンの検出用キットおよび方法 | |
WO2008064884A1 (en) | Activated her3 as a marker for predicting therapeutic efficacy | |
KR101832199B1 (ko) | 악성 종양의 진단 방법 | |
CA2813098C (en) | Means and methods for diagnosing cancer using an antibody which specifically binds to braf v600e | |
US20050214301A1 (en) | Antibodies specific for BCR-ABL fusion protein and uses thereof | |
CA2405448A1 (en) | Method of examining cancer by assaying autoantibody against mdm2 and reagent therefor | |
US7105642B2 (en) | Monoclonal antibodies specific for phosphorylated estrogen receptor alpha (Ser118) and uses thereof | |
JPWO2007055340A1 (ja) | Ptx3高感度測定法 | |
JP6840136B2 (ja) | 黒色腫の診断マーカーとしてのgdf−15 | |
JP4164804B2 (ja) | 酒石酸抵抗性酸性ホスファターゼ5bに特異的なモノクローナル抗体およびその用途 | |
WO2001079266A1 (fr) | Anticorps anti-recepteur du facteur de croissance du keratinocyte humain | |
EP4403581A1 (en) | Anti-ck2 alpha antibody or fragment thereof | |
JPH0643167A (ja) | 癌マーカーであるテネイシン及びその定量法 | |
WO2018034332A1 (ja) | EphA2 N末端フラグメント抗体 | |
JP2000508889A (ja) | ヒト成長ホルモン(hGH)結合性モノクローナル抗体 | |
JP2003180345A (ja) | 遊離型肝細胞増殖因子受容体の測定方法 | |
JPWO2004039844A1 (ja) | 前立腺癌腫瘍マーカー |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040908 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070703 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20071001 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20071112 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20071031 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20071210 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20080214 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080325 |